The "Pharmaceutical Contract Research Services Market by Scale of Operation, Target Therapeutic Areas and Key Geographies and Rest of the World): Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
This report features an extensive study on contract service providers engaged in discovery, preclinical and clinical research of small molecule drugs. The study features in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.
Small molecule drugs account for nearly 90% of the contemporary therapeutics pipeline. In 2020, the US FDA's Center for Drug Evaluation and Research approved 35 small molecule drugs, representing 66% of the total number of new molecular entities (NMEs) clearing regulatory review in the same year. It is worth highlighting that the process of drug development, beginning from the discovery of a pharmacological lead to the commercialization of a clinically validated product, takes around 10-15 years. Moreover, drug discovery and clinical research are capital intensive processes, which, on average, require investments in the range of USD 4-10 billion.
Further, it is a well-known fact that only a small proportion of lead molecules that are shortlisted for further investigation durin the discovery phase, actually make it into the clinical phase, and an even lesser number of product candidates enter the market. Therefore, to optimize on internal resource utilization and save costs, innovator companies in the pharmaceutical industry are increasingly outsourcing various aspects of their discovery-stage operations to specialty contract research organizations (CROs).
Key Questions Answered
Amongst other elements, the report includes:
Key Topics Covered:
2. EXECUTIVE SUMMARY
4. PHARMACEUTICAL CONTRACT RESEARCH SERVICE PROVIDERS: MARKET LANDSCAPE
5. COMPANY PROFILES
6. COMPANY COMPETITIVENESS ANALYSIS
7. PARTNERSHIPS AND COLLABORATIONS
8. MERGERS AND ACQUISITIONS
9. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10. TOTAL COST OF OWNERSHIP IN PHARMACEUTICAL CONTRACT RESEARCH ORGANIZATION
11. CASE STUDY: BIOPHARMACEUTICAL CONTRACT RESEARCH SERVICES MARKET
12. EXECUTIVE INSIGHTS
13. CONCLUDING REMARKS
14. APPENDIX 1: TABULATED DATA
For more information about this report visit https://www.researchandmarkets.com/r/blbr2q
View source version on businesswire.com:
[ Back To CustomerZone360's Homepage ]